Arcturus Therapeutics Holdings (ARCT) Earnings Date & Reports

Key Takeaways

• Earnings release scheduled: Arcturus Therapeutics will report second quarter 2026 financial results after market close on Thursday, August 6, 2026, followed by a conference call at 4:30 p.m. Eastern Time.
• Consensus estimates point to a wide loss: Wall Street analysts expect an earnings per share (EPS) loss of approximately $1.00 and revenue near $3.2 million, a dramatic decline from $28.3 million in revenue and a loss of $0.34 per share in the same quarter last year.
• Revenue trajectory remains under pressure: The steep year-over-year revenue decline reflects the ongoing wind-down of COVID-19 collaboration revenue tied to the company's partnership with CSL Seqirus.
• Pipeline execution is the real story: Investors will focus intently on clinical updates for ARCT-032, the company's inhaled mRNA therapy for cystic fibrosis (CF), and regulatory progress for ARCT-810 in ornithine transcarbamylase (OTC) deficiency.
• Stock near multi-year lows: ARCT shares closed at $5.76 on July 27, 2026, down more than 60% over the past year and hovering just above the 52-week low of $5.50.
• Balance sheet remains a relative strength: As of March 31, 2026, the company held $213.4 million in cash, cash equivalents, and restricted cash, with a runway extending beyond the second quarter of 2028.

Earnings Context and Why It Matters

Arcturus Therapeutics occupies a distinctive position in the biotechnology landscape as one of the few pure-play mRNA (messenger RNA) medicines companies with both a commercialized product and a clinical-stage pipeline. While KOSTAIVE — the world's first approved self-amplifying mRNA (sa-mRNA) COVID-19 vaccine — validated the company's platform technology, the commercial revenue opportunity has been limited and largely dependent on partner-driven sales in Japan. The upcoming Q2 2026 report arrives at a pivotal moment: revenue from legacy COVID-related collaborations is rapidly diminishing, and the company's investment narrative now rests almost entirely on the progress of its rare disease pipeline, particularly ARCT-032 for cystic fibrosis. For investors, this earnings report serves less as a financial scorecard and more as a critical checkpoint on clinical and regulatory execution.

Earnings Expectations

Analysts expect Arcturus to report a steep drop in revenue for the second quarter of 2026. The consensus revenue estimate sits at approximately $3.2 million, according to data aggregator Finviz, which would represent a decline of roughly 89% from the $28.3 million reported in the second quarter of 2025. On the bottom line, the consensus EPS estimate stands at a loss of approximately $1.00 per share, compared with a loss of $0.34 per share in the prior-year quarter.

The sharp contraction in revenue is not unexpected. In the first quarter of 2026, the company reported revenue of just $2.06 million — well below the consensus estimate of approximately $6.3 million — while delivering an EPS loss of $0.95, which beat expectations by a modest margin. That pattern of declining top-line results paired with disciplined expense management is likely to repeat. Research and development (R&D) expenses fell $13.4 million year-over-year in Q1 2026 as large COVID-19 vaccine development programs wound down, and general and administrative (G&A) costs also declined.

Historically, Arcturus has beaten consensus EPS estimates in six of the last eight quarters, though revenue has been more volatile. The stock's post-earnings reactions have been mixed: shares gained 3.6% the day after Q1 2026 results but fell 4.2% following the Q4 2025 report. The Q2 2025 report in August 2025 triggered a 30.7% surge, underscoring how sensitive ARCT shares are to clinical pipeline updates rather than financial figures alone.

AI Screener

For investors seeking to identify earnings-driven opportunities beyond individual stock analysis, Tickeron's AI Screener offers a powerful AI-driven stock and ETF discovery platform. The tool enables traders and investors to scan thousands of securities using customizable filters that span technical patterns, fundamental metrics, market capitalization, volatility profiles, and proprietary AI-generated signals. Whether searching for breakout candidates, sector-level momentum, or contrarian setups ahead of earnings events, the AI Screener is designed to streamline the discovery process far more efficiently than manual screening. For those watching the biotechnology and mRNA therapeutics space, it provides a data-rich way to monitor emerging opportunities alongside names like Arcturus Therapeutics.

Market Reaction and Investor Sentiment

Investor sentiment heading into the Q2 2026 report is distinctly cautious. ARCT shares have declined approximately 21% over the past month and are trading near their lowest levels in several years. The stock's beta of 2.36 indicates significantly higher volatility than the broader market, and the current price action reflects a market that is pricing in limited near-term revenue visibility. Despite the depressed share price, analyst sentiment remains notably constructive: the consensus rating stands at Strong Buy, with an average 12-month price target of approximately $20.60 — more than three times the current trading level. This wide gap between analyst targets and market pricing suggests that a significant portion of institutional investors views the current valuation as disconnected from the pipeline's long-term potential, but near-term catalysts are needed to bridge that gap. Key sentiment risks heading into the print include the possibility of slower-than-expected enrollment in the ARCT-032 Phase 2 study and any signs that the FDA (U.S. Food and Drug Administration) end-of-Phase-2 meeting timeline for ARCT-810 could slip beyond the second half of 2026.

Forward Outlook and Key Factors to Monitor

Looking beyond the Q2 2026 report, the investment case for Arcturus hinges on several closely watched catalysts that could reshape the narrative over the next 12 months.

The most visible near-term catalyst is the ARCT-032 cystic fibrosis program. The company initiated enrollment in a 12-week open-label Phase 2 study during the first quarter of 2026, earlier than originally anticipated. This trial enrolls Class I CF participants and monitors lung function metrics such as percent-predicted FEV1 (forced expiratory volume in one second) and LCI (lung clearance index), along with high-resolution computed tomography (HRCT) imaging. Any interim data or safety updates on the ongoing 10 mg and 15 mg dosing cohorts could serve as a meaningful sentiment driver. The company has already demonstrated that repeat inhaled mRNA dosing beyond one month is tolerable — an important de-risking milestone.

The second major catalyst is the ARCT-810 program for OTC deficiency. Following productive Type C meetings with the FDA, the company is collecting additional exploratory data to support an end-of-Phase-2 meeting planned for the second half of 2026. Clarity on a pediatric pivotal trial pathway would represent a significant regulatory milestone and could broaden the addressable patient population considerably.

On the commercial front, partner Meiji is actively manufacturing KOSTAIVE in a two-dose vial presentation for the 2026–2027 season in Japan. While Arcturus does not directly guide on KOSTAIVE revenue, any commentary on partner-driven demand signals or manufacturing scale will be parsed for clues about the vaccine's commercial trajectory.

Financially, the company's cash position of $213.4 million provides a comfortable multi-year runway, but the pace of cash burn — approximately $19.4 million in Q1 2026 alone — bears watching. With revenue likely to remain modest until pipeline assets advance toward commercialization, disciplined expense management will remain an underappreciated but critical component of the story.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations